Silexsyn

Silexsyn is a second-generation silicon-based derivative of indomethacin (sila-indomethacin) developed by Silamed and the University of Wisconsin-Madison. It functions as a potent and selective inhibitor of cyclooxygenase-2 (COX-2) and also inhibits the transcription activating function of NF-κB. By incorporating a silicon atom into the indomethacin scaffold, Silexsyn achieves high selectivity for COX-2 over COX-1, potentially reducing the gastrointestinal and renal toxicities associated with non-selective NSAIDs. Preclinical studies have demonstrated its efficacy as an anticancer agent in animal models of non-small cell lung cancer and pancreatic cancer, showing synergistic effects when combined with EGFR inhibitors.

Other names

sila-indomethacinsila-IM derivative